Trial Profile
Study of axitinib as second-line treatment in locally advanced and metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- 21 Sep 2018 New trial record
- 01 Sep 2018 Results published in the Anticancer Research